Two kinds of conditioning before matched stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old (children aren’t included).
- You have a qualifying blood cancer such as AML, MDS, CML, multiple myeloma, CLL, or certain types of lymphoma, and it must fit the trial’s disease-status rules.
- Your transplant must be from a donor who matches your HLA type closely (matched sibling or a 10/10 matched unrelated donor).
- Your health (heart, lungs, liver, and overall strength) must be good enough for transplant, and you can’t have serious organ failure (dialysis for kidney failure is allowed).
- You must be able to use the required transplant medicines (melphalan and Thymoglobulin).
- You can’t have HIV, uncontrolled infection, or certain brain/CNS disease that isn’t responding to treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
Hear when a new Acute Myeloid Leukemia in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.